ArticleCancer chemotherapy and pharmacology2022

Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma.

Ryan H Moy et al.PubMed ↗Publisher ↗

No numbers read from the abstract.